Please assess the completion status of the following clinical trial:

Trial Title: Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurred greater than 90 days after initial treatment~* At least 1 measurable lesion~* Only 1 prior chemotherapy~* Must be over 18 years of age~* ECOG performance status of 0 - 2~* Adequate hematologic, renal, and hepatic function~Exclusion Criteria:~* No prior use of topotecan, docetaxel, or irinotecan~* No symptomatic brain metastases~* History of cardiac arrhythmias, congestive heart failure, stroke, or embolic events~* No prior investigational agents within 1 month prior~* Lung cancer of mixed histology~* Known uncontrolled seizure disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: OTHER): Weekly intravenous topotecan with intravenous docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).